Summary Org OD 14 (tibilone) is a synthetic steroid, designed to combine the favourable effects of oestrogens, progestagens and androgens into a single substance for use as hormone replacement therapy (HRT). Given its antiovulatory properties, the ability to control menopausal symptoms and blocking action on progesterone receptors, Org OD 14 was considered as an agent with potential anti-cancer activity while at the same time helping existing menopausal symptoms. In this phase II study, 14 post-menopausal women with advanced or metastatic breast cancer, who had failed on tamoxifen, were treated with Org OD 14. The median duration of treatment was 12 weeks and all patients stopped because of progressive disease with or without toxicity. Vaginal bleeding occurred in four patients, three of whom had recently stopped tamoxifen. One response was seen: an 82-year-old patient had a partial response in an axillary soft tissue mass, improvement in liver function tests and an improvement in her performance status that lasted over 6 months. One patient with progressive disease on Org OD 14 improved on stopping the drug. In view of the vaginal bleeding, Org OD 14 should not be given to patients who have recently stopped tamoxifen.
Treatment of advanced breast cancer is palliative, with symptom control and quality of life being the main goals. In this situation, tamoxifen is usually the first treatment of choice and gave an overall response rate of 34% in a pooled population of 5353 patients. The average duration of remission was 18 months (Jackson et al., 1991) . Second-line hormone therapy gives response rates from 19% to 38% with a variety of therapies (Wilson et al., 1983 ) and third-line hormone therapy can benefit 42% of patients in terms of disease stabilisation, symptom control or objective response (Iveson et al., 1993) .
Menopausal symptoms, including hot flushes, vaginal dryness, loss of libido and mood changes are often induced by chemotherapy given to pre-and post-menopausal women with both early or advanced breast cancer (Sherwin and Gelfand, 1985) . These symptoms are all effectively controlled by hormone replacement therapy (HRT), but this is usually withheld from patients with breast cancer because of the fear of stimulating or reactivating the cancer. This concern is based on the increased risk of breast cancer in women with a family history of breast cancer or in those with benign breast cancer (Dupont and Page, 1991) . Oestrogens have been used in the treatment of breast cancer for many years. Initially synthetic oestrogens, including diethylstilboestrol and ethinyloestradiol, were reported to give response rates of 30-40% but with a high incidence of side-effects, the most common of which were fluid retention and uterine bleeding (Stoll, 1964) . Premarin, a naturally occurring conjugated oestrogen, has been used at a dose of 2.5 mg three times daily (i.e. 12 times the dose used in HRT) in previously untreated patients with metastatic breast cancer and gave a response rate of 45% with a 24% incidence of uterine bleeding (Smith et al., 1979 (Tax, 1991) .
Org OD 14 is metabolised to other steroid molecules, namely the 4-ene isomer and the 3a-and 3,B-hydroxy metabolites. Human myometrium was used in vitro as a source of progesterone and oestrogen receptors and the 4-ene isomer showed a marked binding to the progesterone receptors, explaining the weak proliferative effect of this drug on the endometrium in vivo.
In a placebo-controlled study in post-menopausal women, no net bone loss was noted in the patients receiving Org OD 14, but patients receiving placebo continued to lose bone at the predicted rate (Lindsay et al., 1978) . Org OD 14 has been shown to be effective in the treatment of menopausal symptoms in a double-blind multicentre cross-over study vs placebo (Tax et al., 1987; Trevoux et al., 1983) . Given its antiovulatory properties, the ability to control menopausal symptoms and blocking action on progesterone receptors, Org OD 14 was considered as an agent with potential anticancer activity while at the same time helping existing menopausal symptoms.
This was a phase II study of the use of Org OD 14 in women with breast cancer who had failed tamoxifen therapy.
Patients and methods Patients
Post-menopausal patients with histologically proven breast carcinoma who had locally advanced or metastatic disease, in whom further endocrine therapy was considered a suitable treatment option, as they had previously received tamoxifen, were entered into this study. 
Patient characteristics
Fourteen patients were entered into the study (Table I ). The median age of the 14 post-menopausal patients was 63 years (range 43-83 years). Six patients had received chemotherapy (one adjuvant) in addition to hormone therapy. All patients had assessable disease: six patients had metastatic disease in only one site, four patients had disease in two sites and four patients had disease at three sites. The sites of disease were bone in 13 patients, liver in two patients, locoregional disease in three patients, lung in four patients, skin in three patients and mediastinum in one patient. 
